Sakar Healthcare Signs Oncology Supply Deal with Zydus
Advertisement
The partnership focuses on the distribution of a range of cancer treatment drugs, aimed at improving access to oncology care in the region while strengthening both companies’ global footprint.
Sakar Healthcare has signed an agreement with Zydus Lifesciences to supply oncology products across the GCC (Gulf Cooperation Council) markets, marking a strategic move to expand its presence in the Middle East.
The partnership focuses on the distribution of a range of cancer treatment drugs, aimed at improving access to oncology care in the region while strengthening both companies’ global footprint.
Under the agreement, Sakar Healthcare will leverage its manufacturing capabilities to supply oncology formulations, while Zydus Lifesciences will support the commercialization and market reach in GCC countries.
The deal is expected to help address the growing demand for cancer therapies in the region, where the burden of oncology cases continues to rise. By combining their strengths, both companies aim to ensure a steady and reliable supply of critical medicines.
The collaboration aligns with Sakar Healthcare’s strategy to expand its international business, particularly in regulated and semi-regulated markets. The GCC region has emerged as a key focus area due to increasing healthcare investments, improving infrastructure, and rising awareness around cancer diagnosis and treatment.
For Zydus Lifesciences, the agreement further strengthens its oncology portfolio and enhances its presence in global markets.
The companies highlighted that the partnership will focus on maintaining high-quality standards and regulatory compliance while delivering affordable treatment options. The move is also expected to create new growth opportunities and reinforce their position in the oncology segment.
This agreement comes at a time when access to oncology drugs remains a critical challenge in several parts of the world. Through this collaboration, Sakar Healthcare and Zydus Lifesciences aim to bridge gaps in availability and contribute to better patient outcomes across GCC markets.
Stay tuned for more such updates on Digital Health News
